Hemogenyx Pharmaceuticals plc

(“Hemogenyx Pharmaceuticals” or the “Company”)

 

Result of General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the General Meeting held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

General Meeting Voting Results

Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes withheld (2)
1. To grant the Directors the authority to issue the Convertible Loan Notes 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000
2. To authorise the allotment of shares and the right to subscribe for or convert any security into shares 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000
Special Resolutions Votes for % of votes cast for Votes against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes withheld (2)
3. To disapply statutory pre-emption provisions 152,836,161 99.93% 110,000 0.07% 152,946,161 35.27% 10,000
  1. The Company’s issued share capital (“ISC”) on 4 January 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 433,636,255 ordinary shares.
  2. A ‘vote withheld’ in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

 

 

Enquiries:

Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow